Arcus and Gilead terminate development for etrumadenant in prostate cancer

Arcus and Gilead terminate development for etrumadenant in prostate cancer

Source: 
Clinical Trials Arena
snippet: 

Arcus Biosciences and Gilead Sciences have deprioritised the development of etrumadenant in castrate-resistant prostate cancer after the drug showed an underwhelming response on radiographic progression-free survival (rPFS) in an ongoing trial.